single-pass membrane protein with coiled-coil domains 4Genealiases: C11orf75 · FN5
Q-omics provides the consensus-scored SMCO4 profile across patient tissues and cancer cell-line models. SMCO4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SMCO4 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SMCO4 RNA expression shows 17,045 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where SMCO4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMCO4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMCO4 survival associations across molecular data types. SMCO4 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMCO4 RNA expression–survival associations across cancer types. High SMCO4 expression shows unfavorable associations in BRCA, KICH, UVM and LAML, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SMCO4 RNA expression.
This table summarizes SMCO4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SMCO4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMCO4 shows lower tumor expression in THCA, UCEC and KICH and higher tumor expression in KIRC, STAD and LUAD. The KIRC box plot shows higher SMCO4 RNA expression in tumor versus normal tissue (log2 FC = +1.077, t-test p < 0.001).
This table shows molecular features associated with SMCO4 in patient tissues and cancer cell lines. In patient samples, SMCO4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMCO4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
